The combination of raised guidance, strong procedure growth, and higher ASPs suggests improving commercial execution. Traders should monitor first-quarter 2026 revenue ($79–$82M expected) and procedure volume (12,000–12,800) as validation of the new commercial strategy.
Price Chart
Executive Summary
PROCEPT BioRobotics reported Q4 2025 revenue of $76.4 million, up 12% year-over-year, driven by strong handpiece and international sales. The company raised full-year 2026 revenue guidance to $390–$410 million (27–33% growth) despite near-term disruptions from a sales force realignment, citing higher handpiece pricing and strong procedure growth of 39–48%.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $76.4 million (+12% YoY)
- U.S. procedures: ~12,200 (+69% YoY)
- 2026 revenue guidance raised to $390–$410 million (27–33% growth)
- 2026 U.S. procedure growth expected at 39–48%
- Handpiece ASP increased to $3,340 in Q4, with $3,500 expected in 2026
- Gross margin guidance for 2026: ~65%
Financial Impact
Revenue growth accelerating from 37% in 2025 to 27–33% in 2026, with improved gross margins and pricing power
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| U.S. | $66.6M | +10.0% |
| International | $9.8M | +25.0% |
Risk Factors
- Increased operating expenses ($350M expected in 2026) may pressure profitability
- Near-term disruption from sales force realignment could impact execution
- Net loss widened in Q4 2025 to $29.8M vs $18.9M YoY
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001588978-26-000002 |
| Document: prct-20260225.htm | 0001588978-26-000002 |
| Document: 0001588978-26-000002-index-headers.html | 0001588978-26-000002 |
| Document: 0001588978-26-000002-index.html | 0001588978-26-000002 |
| Document: 0001588978-26-000002.txt | 0001588978-26-000002 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 24d ago | 8-K | $17.82 | awaiting T+60 | — | $19.83 (+11.28%) |
Sep 24, 2026 4w ago | 8-K | $17.20 | awaiting T+60 | — | $19.83 (+15.29%) |
Aug 10, 2026 11w ago | Insider Buy | $21.71 | awaiting T+60 | — | $19.83 (−8.66%) |
Jun 11, 2026 19w ago | Institutional Cluster | $27.69 $21.35 | ▼ −22.90% | ▼ −26.72% | $19.83 (−28.39%) |
Jun 10, 2026 19w ago | Insider Cluster | $27.69 $21.35 | ▼ −22.90% | ▼ −26.72% | $19.83 (−28.39%) |
Jun 10, 2026 19w ago | Insider Cluster | $27.69 $21.35 | ▼ −22.90% | ▼ −26.72% | $19.83 (−28.39%) |
Jun 10, 2026 19w ago | Insider Cluster | $27.69 $21.35 | ▼ −22.90% | ▼ −26.72% | $19.83 (−28.39%) |
Mar 10, 2026 33w ago | Insider Cluster | $24.17 $26.33 | ▲ +8.94% | ▼ −2.75% | $19.83 (−17.96%) |
Mar 6, 2026 33w ago | 8-K | $24.22 $27.86 | ▲ +15.03% | ▲ +2.25% | $19.83 (−18.13%) |
Mar 6, 2026 33w ago | Insider Cluster | $24.22 $27.86 | ▲ +15.03% | ▲ +2.25% | $19.83 (−18.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers